Concepts (245)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C, Chronic | 25 | 2021 | 37 | 8.020 |
Why?
|
| Hepatitis C | 20 | 2022 | 44 | 6.890 |
Why?
|
| Antiviral Agents | 28 | 2021 | 66 | 6.790 |
Why?
|
| Liver Diseases | 12 | 2022 | 32 | 5.460 |
Why?
|
| Hepacivirus | 21 | 2022 | 31 | 4.450 |
Why?
|
| Liver Transplantation | 9 | 2023 | 93 | 3.850 |
Why?
|
| Pregnancy Complications | 7 | 2022 | 46 | 3.500 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 5 | 2024 | 6 | 2.180 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2020 | 12 | 1.900 |
Why?
|
| Liver Cirrhosis | 11 | 2024 | 37 | 1.690 |
Why?
|
| Pregnancy | 12 | 2022 | 291 | 1.640 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2020 | 8 | 1.530 |
Why?
|
| Humans | 63 | 2024 | 25692 | 1.490 |
Why?
|
| Ribavirin | 7 | 2016 | 8 | 1.330 |
Why?
|
| Hepatitis B | 5 | 2019 | 12 | 1.210 |
Why?
|
| United States | 19 | 2022 | 1943 | 1.200 |
Why?
|
| Liver Neoplasms | 4 | 2022 | 93 | 1.190 |
Why?
|
| HIV Infections | 4 | 2021 | 457 | 1.170 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2022 | 26 | 1.140 |
Why?
|
| Interferon-alpha | 4 | 2012 | 30 | 1.120 |
Why?
|
| Polyethylene Glycols | 4 | 2012 | 36 | 1.110 |
Why?
|
| Sulfonamides | 6 | 2020 | 40 | 1.110 |
Why?
|
| Female | 35 | 2024 | 14273 | 1.070 |
Why?
|
| Hepatitis, Autoimmune | 2 | 2024 | 5 | 1.060 |
Why?
|
| Societies, Medical | 3 | 2022 | 138 | 0.980 |
Why?
|
| Quinoxalines | 4 | 2020 | 4 | 0.870 |
Why?
|
| Carbamates | 8 | 2020 | 8 | 0.830 |
Why?
|
| Gastroenterology | 3 | 2017 | 10 | 0.790 |
Why?
|
| Treatment Outcome | 18 | 2021 | 3231 | 0.790 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2021 | 40 | 0.780 |
Why?
|
| Living Donors | 1 | 2021 | 15 | 0.750 |
Why?
|
| Prejudice | 1 | 2021 | 31 | 0.750 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 107 | 0.710 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 20 | 0.700 |
Why?
|
| Patient Selection | 1 | 2021 | 170 | 0.700 |
Why?
|
| Postoperative Hemorrhage | 1 | 2020 | 24 | 0.700 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 38 | 0.700 |
Why?
|
| Benzimidazoles | 3 | 2019 | 8 | 0.690 |
Why?
|
| Drug Therapy, Combination | 10 | 2021 | 163 | 0.690 |
Why?
|
| Kidney Transplantation | 2 | 2018 | 120 | 0.690 |
Why?
|
| Genotype | 9 | 2017 | 326 | 0.650 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2019 | 2 | 0.640 |
Why?
|
| Viral Load | 5 | 2016 | 69 | 0.640 |
Why?
|
| Adult | 20 | 2021 | 7336 | 0.630 |
Why?
|
| Obesity | 1 | 2021 | 290 | 0.620 |
Why?
|
| Algorithms | 2 | 2020 | 347 | 0.620 |
Why?
|
| Fear | 1 | 2018 | 44 | 0.600 |
Why?
|
| Cholestasis, Intrahepatic | 3 | 2019 | 4 | 0.590 |
Why?
|
| Liver | 3 | 2022 | 144 | 0.580 |
Why?
|
| Middle Aged | 20 | 2021 | 8403 | 0.550 |
Why?
|
| Drugs, Generic | 1 | 2016 | 1 | 0.540 |
Why?
|
| Antacids | 1 | 2016 | 1 | 0.530 |
Why?
|
| Proton Pump Inhibitors | 1 | 2016 | 13 | 0.530 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2016 | 2 | 0.520 |
Why?
|
| Sustained Virologic Response | 6 | 2021 | 6 | 0.520 |
Why?
|
| Virology | 1 | 2015 | 2 | 0.510 |
Why?
|
| Cyclopropanes | 4 | 2020 | 13 | 0.500 |
Why?
|
| Sofosbuvir | 5 | 2019 | 5 | 0.490 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 5 | 2019 | 5 | 0.490 |
Why?
|
| Length of Stay | 2 | 2016 | 300 | 0.480 |
Why?
|
| Patient Readmission | 1 | 2016 | 116 | 0.470 |
Why?
|
| Liver Function Tests | 3 | 2022 | 19 | 0.470 |
Why?
|
| Coinfection | 3 | 2019 | 19 | 0.460 |
Why?
|
| Young Adult | 8 | 2021 | 1855 | 0.450 |
Why?
|
| Heart Failure | 1 | 2016 | 166 | 0.440 |
Why?
|
| Male | 22 | 2021 | 13917 | 0.440 |
Why?
|
| Patient Reported Outcome Measures | 6 | 2021 | 450 | 0.430 |
Why?
|
| Preventive Health Services | 1 | 2013 | 11 | 0.430 |
Why?
|
| Advisory Committees | 1 | 2013 | 19 | 0.430 |
Why?
|
| Health Policy | 1 | 2013 | 42 | 0.420 |
Why?
|
| Periodicals as Topic | 2 | 2023 | 41 | 0.420 |
Why?
|
| Retrospective Studies | 9 | 2024 | 3220 | 0.410 |
Why?
|
| Disease Management | 2 | 2016 | 97 | 0.400 |
Why?
|
| Prognosis | 4 | 2022 | 739 | 0.390 |
Why?
|
| Hepatitis C Antibodies | 2 | 2022 | 4 | 0.390 |
Why?
|
| Imidazoles | 4 | 2020 | 53 | 0.360 |
Why?
|
| RNA, Viral | 4 | 2022 | 44 | 0.360 |
Why?
|
| Pregnancy Outcome | 2 | 2021 | 17 | 0.340 |
Why?
|
| Drug Resistance, Viral | 4 | 2017 | 12 | 0.340 |
Why?
|
| Proline | 3 | 2019 | 9 | 0.330 |
Why?
|
| Lactams, Macrocyclic | 3 | 2019 | 4 | 0.330 |
Why?
|
| Mass Screening | 4 | 2021 | 168 | 0.330 |
Why?
|
| Aged | 13 | 2020 | 8501 | 0.320 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2008 | 3 | 0.300 |
Why?
|
| Motivation | 3 | 2023 | 89 | 0.300 |
Why?
|
| Cohort Studies | 6 | 2021 | 1781 | 0.290 |
Why?
|
| Fatty Liver | 2 | 2019 | 30 | 0.290 |
Why?
|
| Anemia | 1 | 2008 | 88 | 0.280 |
Why?
|
| Drug Administration Schedule | 2 | 2018 | 152 | 0.270 |
Why?
|
| Recombinant Proteins | 4 | 2012 | 201 | 0.270 |
Why?
|
| Risk Factors | 4 | 2020 | 2224 | 0.270 |
Why?
|
| Benzofurans | 3 | 2020 | 6 | 0.250 |
Why?
|
| Graft Rejection | 2 | 2018 | 63 | 0.250 |
Why?
|
| Prevalence | 2 | 2020 | 435 | 0.250 |
Why?
|
| Valine | 4 | 2019 | 6 | 0.240 |
Why?
|
| Adolescent | 3 | 2020 | 2076 | 0.230 |
Why?
|
| Cost-Benefit Analysis | 4 | 2021 | 124 | 0.230 |
Why?
|
| Incidence | 2 | 2020 | 731 | 0.230 |
Why?
|
| Risk Assessment | 3 | 2018 | 618 | 0.230 |
Why?
|
| Prospective Studies | 4 | 2019 | 1633 | 0.220 |
Why?
|
| Pyrrolidines | 3 | 2018 | 11 | 0.220 |
Why?
|
| Amides | 2 | 2020 | 16 | 0.220 |
Why?
|
| Benzamides | 1 | 2023 | 14 | 0.210 |
Why?
|
| Vaccination | 1 | 2023 | 31 | 0.210 |
Why?
|
| Chronic Disease | 3 | 2020 | 403 | 0.210 |
Why?
|
| Ritonavir | 3 | 2019 | 3 | 0.210 |
Why?
|
| Macrocyclic Compounds | 3 | 2019 | 3 | 0.210 |
Why?
|
| Uracil | 3 | 2019 | 4 | 0.210 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2022 | 5 | 0.210 |
Why?
|
| RNA | 1 | 2022 | 36 | 0.200 |
Why?
|
| Fibrosis | 1 | 2022 | 28 | 0.200 |
Why?
|
| History, 20th Century | 1 | 2022 | 39 | 0.200 |
Why?
|
| Selection Bias | 1 | 2021 | 7 | 0.190 |
Why?
|
| Graft Survival | 2 | 2019 | 92 | 0.190 |
Why?
|
| Fertility | 1 | 2021 | 16 | 0.190 |
Why?
|
| Aged, 80 and over | 7 | 2020 | 4459 | 0.180 |
Why?
|
| Tissue Donors | 1 | 2021 | 61 | 0.180 |
Why?
|
| World Health Organization | 1 | 2020 | 10 | 0.180 |
Why?
|
| End Stage Liver Disease | 1 | 2020 | 13 | 0.180 |
Why?
|
| Critical Care | 1 | 2022 | 180 | 0.170 |
Why?
|
| Pandemics | 1 | 2022 | 227 | 0.170 |
Why?
|
| Recurrence | 2 | 2011 | 275 | 0.170 |
Why?
|
| Anilides | 2 | 2019 | 7 | 0.170 |
Why?
|
| 2-Naphthylamine | 2 | 2019 | 3 | 0.170 |
Why?
|
| Attitude of Health Personnel | 1 | 2021 | 146 | 0.170 |
Why?
|
| Hemorrhage | 1 | 2020 | 75 | 0.170 |
Why?
|
| Consensus | 2 | 2021 | 90 | 0.170 |
Why?
|
| Drug and Narcotic Control | 2 | 2016 | 3 | 0.160 |
Why?
|
| Forecasting | 1 | 2019 | 92 | 0.160 |
Why?
|
| Hyperemesis Gravidarum | 1 | 2019 | 1 | 0.160 |
Why?
|
| United States Food and Drug Administration | 2 | 2016 | 22 | 0.160 |
Why?
|
| Biomedical Research | 1 | 2019 | 57 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 3 | 2021 | 284 | 0.160 |
Why?
|
| Medication Adherence | 1 | 2019 | 72 | 0.160 |
Why?
|
| Follow-Up Studies | 4 | 2015 | 1689 | 0.160 |
Why?
|
| Aminoisobutyric Acids | 1 | 2018 | 1 | 0.160 |
Why?
|
| Leucine | 1 | 2018 | 10 | 0.150 |
Why?
|
| Logistic Models | 2 | 2010 | 366 | 0.150 |
Why?
|
| Transplant Recipients | 1 | 2018 | 20 | 0.150 |
Why?
|
| Internationality | 1 | 2018 | 24 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 325 | 0.140 |
Why?
|
| Time Factors | 3 | 2016 | 1336 | 0.140 |
Why?
|
| Infant, Newborn | 1 | 2019 | 588 | 0.140 |
Why?
|
| Drug Substitution | 1 | 2017 | 4 | 0.140 |
Why?
|
| Critical Pathways | 1 | 2017 | 20 | 0.140 |
Why?
|
| Psychometrics | 1 | 2018 | 216 | 0.140 |
Why?
|
| Patient Participation | 1 | 2017 | 42 | 0.140 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 913 | 0.140 |
Why?
|
| Counterfeit Drugs | 1 | 2016 | 1 | 0.130 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 1077 | 0.130 |
Why?
|
| Drug Approval | 1 | 2016 | 7 | 0.130 |
Why?
|
| Commerce | 1 | 2016 | 11 | 0.130 |
Why?
|
| Canada | 1 | 2016 | 48 | 0.130 |
Why?
|
| Ascites | 1 | 2016 | 4 | 0.130 |
Why?
|
| Hospitalization | 2 | 2016 | 292 | 0.130 |
Why?
|
| Safety | 1 | 2016 | 40 | 0.130 |
Why?
|
| Quality Control | 1 | 2016 | 32 | 0.130 |
Why?
|
| Fraud | 1 | 2016 | 14 | 0.130 |
Why?
|
| Paracentesis | 1 | 2016 | 4 | 0.130 |
Why?
|
| Interferons | 1 | 2016 | 7 | 0.130 |
Why?
|
| Eclampsia | 1 | 2016 | 1 | 0.130 |
Why?
|
| HELLP Syndrome | 1 | 2016 | 2 | 0.130 |
Why?
|
| Pre-Eclampsia | 1 | 2016 | 6 | 0.130 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2016 | 133 | 0.130 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 29 | 0.130 |
Why?
|
| Administration, Oral | 1 | 2015 | 103 | 0.120 |
Why?
|
| Benchmarking | 1 | 2015 | 37 | 0.120 |
Why?
|
| Kidney Failure, Chronic | 1 | 2017 | 148 | 0.120 |
Why?
|
| Comorbidity | 4 | 2018 | 457 | 0.120 |
Why?
|
| Benzazepines | 1 | 2015 | 4 | 0.120 |
Why?
|
| Isoquinolines | 1 | 2015 | 12 | 0.120 |
Why?
|
| Deficiency Diseases | 1 | 2015 | 2 | 0.120 |
Why?
|
| Indoles | 1 | 2015 | 35 | 0.120 |
Why?
|
| Liver Failure | 1 | 2015 | 10 | 0.120 |
Why?
|
| Treatment Failure | 2 | 2017 | 154 | 0.120 |
Why?
|
| Zinc | 1 | 2015 | 41 | 0.120 |
Why?
|
| Phenotype | 1 | 2015 | 292 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 311 | 0.120 |
Why?
|
| Hospitalists | 1 | 2014 | 5 | 0.110 |
Why?
|
| Off-Label Use | 1 | 2014 | 6 | 0.110 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 299 | 0.110 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 74 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2014 | 75 | 0.110 |
Why?
|
| Internship and Residency | 1 | 2016 | 196 | 0.110 |
Why?
|
| Quality of Health Care | 1 | 2014 | 117 | 0.100 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 443 | 0.100 |
Why?
|
| Monitoring, Immunologic | 1 | 2012 | 1 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 100 | 0.090 |
Why?
|
| Cost of Illness | 1 | 2011 | 44 | 0.090 |
Why?
|
| Drug Carriers | 1 | 2010 | 7 | 0.090 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2021 | 21 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 111 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2011 | 120 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2010 | 244 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 472 | 0.080 |
Why?
|
| Fluorenes | 2 | 2019 | 2 | 0.080 |
Why?
|
| Hemoglobins | 1 | 2008 | 72 | 0.070 |
Why?
|
| Viral Nonstructural Proteins | 2 | 2017 | 4 | 0.070 |
Why?
|
| Drug Combinations | 2 | 2017 | 34 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 847 | 0.070 |
Why?
|
| Hospital Costs | 2 | 2016 | 59 | 0.060 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2022 | 1 | 0.050 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2022 | 1 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 8 | 0.050 |
Why?
|
| Hypoxia | 1 | 2022 | 35 | 0.050 |
Why?
|
| Pregnant Women | 1 | 2021 | 10 | 0.050 |
Why?
|
| Waiting Lists | 1 | 2019 | 16 | 0.040 |
Why?
|
| Tissue and Organ Procurement | 1 | 2019 | 24 | 0.040 |
Why?
|
| Insurance, Major Medical | 1 | 2018 | 1 | 0.040 |
Why?
|
| International Normalized Ratio | 1 | 2018 | 18 | 0.040 |
Why?
|
| Registries | 1 | 2019 | 170 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 44 | 0.040 |
Why?
|
| Quality of Life | 1 | 2022 | 600 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2017 | 88 | 0.040 |
Why?
|
| Uridine Monophosphate | 1 | 2017 | 1 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 46 | 0.030 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2017 | 24 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 51 | 0.030 |
Why?
|
| Internal Medicine | 1 | 2016 | 24 | 0.030 |
Why?
|
| Career Choice | 1 | 2016 | 30 | 0.030 |
Why?
|
| Pain Management | 1 | 2018 | 136 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2018 | 159 | 0.030 |
Why?
|
| Cost Savings | 1 | 2016 | 36 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 35 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 646 | 0.030 |
Why?
|
| Curriculum | 1 | 2016 | 136 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2017 | 130 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2016 | 131 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2015 | 60 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 119 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 157 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 329 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 231 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2016 | 217 | 0.030 |
Why?
|
| Drug Industry | 1 | 2014 | 6 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 308 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2014 | 41 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2014 | 59 | 0.030 |
Why?
|
| Inpatients | 1 | 2014 | 132 | 0.030 |
Why?
|
| Disease Progression | 1 | 2015 | 664 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2012 | 29 | 0.020 |
Why?
|
| Immunoassay | 1 | 2012 | 38 | 0.020 |
Why?
|
| Probability | 1 | 2012 | 71 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 124 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2012 | 827 | 0.020 |
Why?
|